CDH3

Across TCGA pan-cancer cohorts, CDH3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDH3 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDH3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDH3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CDH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.251	0.473	.010	20	view →
LUAD	OS	Tertile	All	0.748	1.000	.017	15	view →
HNSC	DFS	Quartile	All	1.000	0.310	.033	6	view →
CCRCC	DFS	Median	III,IV	1.000	0.358	.041	2	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDH3–PDAC (DFS)

Open the PDAC breakdown →